Hospital
SMSJ Tucson Holdings, LLC
SMSJ Tucson Holdings, LLC was paid $2.95M by Medicaid between Mar 2020 and Dec 2024, across 55 billing codes. Its largest line is 99283, emergency room visit (moderate) — 40% of everything it billed.
33Billing provider infoSMSJ TUCSON HOLDINGS, LLC
TUCSON, AZ 85742
TUCSON, AZ 85742
33aNPI1487218509assigned 04/24/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.95M
24GClaims53,295
24DCodes billed55
24AFirst – last monthMar 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#52 of 78
Median peer was paid$12.21M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 3,480 | $165K | |
| 2021 | 10,991 | $525K | |
| 2022 | 13,286 | $708K | |
| 2023 | 14,746 | $849K | |
| 2024incomplete | 10,792 | $699K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 40% | 7,301 | 6,901 | $1.17M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 3,948 | 3,758 | $774K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 13% | 722 | 688 | $386K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.4% | 1,698 | 1,618 | $247K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.9% | 1,437 | 1,407 | $145K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.9% | 593 | 573 | $144K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 120 | 116 | $49K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 364 | 352 | $18K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,733 | 1,571 | $16K |
| 87070 | <1% | 230 | 227 | $324.05 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 733 | 718 | $315.33 |
| 84484 | <1% | 1,064 | 956 | $288.80 |
43 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,239 | $244.72 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,724 | $242.95 |
| 71045 | Radiologic examination, chest; single view | <1% | 1,196 | $232.50 |
| 87807 | <1% | 139 | $82.36 | |
| 80053 | Comprehensive metabolic panel | <1% | 4,863 | $73.46 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 806 | $52.59 |
| 81025 | <1% | 1,834 | $16.21 | |
| 81003 | <1% | 3,064 | $4.61 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 2,435 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 1,689 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 1,499 | $0.00 |
| 87088 | 0% | 543 | $0.00 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 832 | $0.00 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 0% | 5,161 | $0.00 |
| 87430 | 0% | 536 | $0.00 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 0% | 299 | $0.00 |
| 83605 | 0% | 182 | $0.00 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 1,057 | $0.00 |
| 96376 | 0% | 140 | $0.00 | |
| 83735 | 0% | 14 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 26 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 400 | $0.00 |
| 36416 | 0% | 14 | $0.00 | |
| 82150 | 0% | 15 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 19 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 41 | $0.00 |
| 80320 | 0% | 13 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 13 | $0.00 |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 14 | $0.00 |
| A9270 | Non-covered item or service | 0% | 26 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 14 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 1,550 | $0.00 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 307 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 35 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,010 | $0.00 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 118 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 274 | $0.00 |
| 82948 | 0% | 91 | $0.00 | |
| 73630 | 0% | 44 | $0.00 | |
| 90715 | 0% | 13 | $0.00 | |
| 94664 | 0% | 38 | $0.00 | |
| 73610 | 0% | 13 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCORMIER, CRISTIAN (CFO)
| Provider | Location | Paid |
|---|---|---|
| SMSJ Tucson Holdings LLC | Tucson, AZ | $29.82M |
| SMSJ Tucson Holdings LLC | Tucson, AZ | $28.93M |
| SMSJ Tucson Holdings LLC | Tucson, AZ | $2.43M |
| SMSJ Tucson Holdings, LLC | Tucson, AZ | $25K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.